Congratulations to our partners AstraZeneca and Bayer | Pharmaceuticals for making the top 10 in @CBInsights Pharma AI Readiness Index! cbinsights.com/research/ai-re…

Congratulations to the UK Biobank and all participating volunteers on this fantastic milestone! A massive contribution to health research.

Delighted to present at the @NHS's Integrated Care Systems Congress, where we gave an overview of how we enable more efficient drug development using our computational imaging #AI models. Thank you to GIANT Health Event for the invitation!

"The goal of what they call 'common-sense oncology' is to prioritize treatments that meaningfully improve survival and quality of life." Such an important initiative led by Drs. Bishal Gyawali, MD, PhD, FASCO, chris booth, Chris Booth, and Elizabeth Eisenhauer.

Fantastic article by Allison DeAngelis on how our team at Altis Labs is using AI to transform clinical trials – thank you for the shoutout! If sponsors focus too heavily on reductionist tumor size measurements to guesstimate efficacy, “they might be pushing a drug into

Excellent overview by Allison DeAngelis on how AI is transforming clinical trials. Our CEO Felix Baldauf-Lenschen explains how we help sponsors like AstraZeneca Bayer | Pharmaceuticals run smaller, faster and more successful trials so that patients get access to most effective novel treatments sooner

Biopharma companies are beginning to turn to AI to enroll people in clinical trials. trib.al/0R11vzW

Find out how Toronto-based Altis Labs is transforming the future of clinical trials and healthcare with AI. statnews.com/2024/04/03/ai-…

Join me on Wednesday for a discussion about Digital Twins in oncology trials here in Toronto at #MaRSImpactHealth, Canada's largest healthcare conference. The panel will include our partners at Bayer | Pharmaceuticals and will be moderated by science journalist Ayesha Rashid. When:

Excited to be back in NYC next week for the AI x Bio Summit!

The Altis Labs team is excited to announce that two abstracts have been accepted at ESMO - Eur. Oncology for poster presentation this year, illustrating our latest research with biopharma partners and research collaborators. Please reach out if you're headed to Barcelona for #ESMO24 this

"There is risk in not acting". Engaging discussions on #AI and #HealthData at #CTOConf2024! This morning’s panel is diving into how data-driven tools are reshaping #clinicaltrials for better precision and outcomes.

Thank you Brittany Trang for featuring the recent results from AstraZeneca's evaluation of our AI models. We have a lot more work to do, but we're excited to begin to showcase how AI can accelerate clinical development with a stronger predictor of overall survival, the gold

We're proud to share that results from AstraZeneca's evaluation of our AI-powered External Control Arm were presented at #ISPOR2025 today. AZ's analysis showed that our ECA replicated survival outcomes of the control arm and preserved the observed treatment effect.

At the Canadian Breast Cancer Symposium, we presented a first glimpse of IPRO’s ability to generalize across cancer types. In this study, our AI model analyzed pretreatment breast cancer scans having trained solely on lung cancer data. Remarkably, IPRO stratified survival

We’re excited to share that we have entered into a collaboration agreement with J&J Innovative Medicine. Trained on the industry’s most comprehensive multimodal real-world dataset, our AI models will support the evaluation of novel outcome measures that have the potential to accelerate